From 095276df864a0383fafab613e1dde6cf1a490d6b Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Tue, 20 Feb 2024 12:50:08 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Update 2024___02.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/STOP2030___Web___Update 2024___02.md b/pages/STOP2030___Web___Update 2024___02.md index 5ade8453..51e06d3e 100644 --- a/pages/STOP2030___Web___Update 2024___02.md +++ b/pages/STOP2030___Web___Update 2024___02.md @@ -88,7 +88,7 @@ - Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation) - Una referencia explícita al Estudio ALIVE: https://gatesopenresearch.org/articles/6-62/v1 - Los achievements de los STOP previos - - Qualification at EMA for [[article]] 58 (ahora se llama Meds4All, creo) + - Qualification at EMA for [[article]] 58 (ahora se llama Meds4All, creo) https://www.ema.europa.eu/en/glossary/article-58-application https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/medicines-use-outside-european-union - Proved safety of ivermectin of up to 600ug/kg both alone and in coformulation with [[albendazole]] - Demonstrated efficacy of the [[FDC]] against T. trichiura -